CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,402 enrolled
Drug / intervention
Biomarkers of inflammationother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04706533
NCT04706533N/ACompleted
CompareCT.gov

Prospective Observational Study Examining Clinical Characteristics, Inflammatory Markers, Treatments and Outcomes of Patients Hospitalized for COVID-19 at the University of Michigan Healthcare System in Ann Arbor

University of Michigan·observational·Posted Jan 13, 2021·Updated Oct 31, 2023

In Brief

An observational study evaluating Biomarkers of inflammation for Covid19 and 3 related conditions. Completed, enrolled 3,402 participants across 1 site.

Detailed Summary

To better understand the role of inflammation in COVID-19, we established the Michigan Medicine COVID-19 Cohort (M2C2). M2C2 is a funded and ongoing cohort which has currently enrolled over 1500 adult patients (≥18 years) with severe COVID-19 admitted at the University of Michigan. The purpose of M2C2 is to define the in-hospital course of these patients and understand the role of inflammation as a determinant of organ injury and outcomes in COVID-19.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19, Kidney Diseases, Inflammation, SARS-CoV Infection
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJan 13, 2021
Enrollment StartMar 23, 2020
Primary CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 5.5 years ago

Interventions

Biomarkers of inflammationother

Biomarkers were measured on blood samples collected within 48 hours of admission